18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer. - Wikidata - awgldk - TriplyDB

18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.

18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.

http://www.wikidata.org/entity/Q37605725

about

Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.

P2860

Q54948216-D3FD24D4-D167-4FB9-8968-7E60E7F93B62

P2860

18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.

http://www.wikidata.org/entity/Q37605725

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.

@en

18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.

@nl

type

label

18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.

@en

18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.

@nl

prefLabel

18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.

@en

18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.

@nl

P1433

Q37605725-9386D3A4-E5BD-41D5-A44F-47EEABA3A99F

P1476

Q37605725-9C411399-2D76-4C30-9BF7-76C5BA40E067

P2093

Q37605725-0D77106F-3137-4E8F-9C19-72DA51AFE6F5

Q37605725-13AE459D-890F-43BF-A2FF-5E1B86A44D59

Q37605725-1A166036-8642-49C8-854B-B80D13F78151

Q37605725-3A7E07B8-D999-430B-B3F0-AB1489614344

Q37605725-606D67C3-A05C-4065-8FC2-943FF4348B90

Q37605725-60D1A5C5-65AF-4522-984C-7CA8E1C68796

Q37605725-62C20A5A-876E-4558-9782-4C91B5C95512

Q37605725-76942328-6A0A-4F3D-9E9A-2952281F53AC

Q37605725-806B1BD1-7587-4EBD-BFFB-7F664B4ADC48

Q37605725-87268B67-C2B1-439A-8E81-EB02A5C2E19D

P2860

Q37605725-27906E1C-E9A0-40A0-AE19-9E30FB03C47C

Q37605725-3286A140-43DA-4853-B19F-7A2F47668600

Q37605725-35721DEA-7B40-4DD4-9BAD-B4C82DA4EB51

Q37605725-38BD72A7-13D7-41A6-8F41-48C30CFA541A

Q37605725-399D1258-70EF-4784-92B4-058C13CD7AC3

Q37605725-5A786ACF-157E-4588-8544-15278401976B

Q37605725-5DE7350D-F68C-4859-AFCE-BE06433EC24E

Q37605725-78C8E4D3-BDA1-4FCF-8302-10AC42BB2D34

Q37605725-7B311B9E-5637-48D3-B629-64801757F5E5

Q37605725-8C6ED54F-E23A-46A7-BA7A-009FA0FA8F0D

P304

Q37605725-3D406364-95F5-4762-B8CB-E003B3048AC8

P31

Q37605725-5E7BB294-4D21-499A-9761-8CF18A3E9AA8

P356

Q37605725-25E9294C-D597-480B-BC5A-A32456742D76

P407

Q37605725-F10D013D-42B5-4C3D-A81D-F0D3E4936BA4

P433

Q37605725-A049532D-B1CF-46F6-B4B6-A3184CE7DA88

P478

Q37605725-D69FDF35-9519-493E-9669-4203D2147CEB

P577

Q37605725-FD979EFE-F8B6-4147-B25B-B5E49565B80D

P698

Q37605725-19C84AB1-F2AE-4AE6-A8E1-CC97E5AF28EB

P932

Q37605725-1BF820F5-CE8B-400B-B577-FB8F80005B7E

P356

MD.0000000000004421

P1433

P1476

18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.

@en

P2093

Hu B Wu

http://www.w3.org/2001/XMLSchema#string

Jian Guan

http://www.w3.org/2001/XMLSchema#string

Lai Y Liu

http://www.w3.org/2001/XMLSchema#string

Long H Chen

http://www.w3.org/2001/XMLSchema#string

Lu Li

http://www.w3.org/2001/XMLSchema#string

Mi Yang

http://www.w3.org/2001/XMLSchema#string

Min Chen

http://www.w3.org/2001/XMLSchema#string

Nan J Xiao

http://www.w3.org/2001/XMLSchema#string

Qin Y Li

http://www.w3.org/2001/XMLSchema#string

Shuang Wang

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Global cancer statistics in the year 2000.

Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.

Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function.

FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.

Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma.

P304

e4421

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000004421

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27472739

http://www.w3.org/2001/XMLSchema#string

P932

5265876

http://www.w3.org/2001/XMLSchema#string